Unicorn investments

building the successful
businesses of tomorrow

Unicorn
investments

building the successful
businesses of tomorrow

Unicorn
investments

building the successful
businesses of tomorrow

We are strong in the oncology field – our current assets address the most common and deadly types of cancer: breast, pancreatic, lung, colorectal, gastric, and glioblastoma.

Yet our portfolio is now expanding into advanced health tech, nano-robotics, AI, virtual reality, telemedicine, data distribution and governance, and other digital health solutions.

In 2023, we’ll be hosting a Demo Day in the UAE, an unparalleled networking opportunity to connect innovators with the financial resources they need to take their projects forward. 

We foresee scaling to 15-20 portfolio companies in 2023-2024.

SECTORS

Artificial Intelligence

COMING SOON

Life Science

COMING SOON
COMING SOON

We connect promising projects with their necessary capital

A
PP
R
O
A
CH
Due Dilligence
Great market opportunities tracking through a rigorous data-driven process
Strategy
-Reduced cost on operational and administrative tasks
-Tactical execution with a strategic vision
Invest
-Financial obstacle removal
-Productivity improvement through Human Capital Investment
Support
Portfolio support
Execute
Scalable process and strategy implementation
Exit
Spotlight the portfolio companies in preparation of exit

Don’t miss our first Demo Day in the UAE!

Coming soon

COMING SOON

51a is an artificial intelligence innovation lab developing multiple AI based solutions. Our lead focus is aimed at combining Big Data with advanced bioinformatics.

COMING SOON

Lab 51a is an innovation lab designed to invent, discover and advance personalized targeted treatments, bioengineered agents, artificial intelligent discovery and other novel therapeutics. Lab 51a also offers external services as a quality control arm for potential acquisitions, ensuring presented data from outside organizations is vetted and verified. This is done by re-running lab-based research to verify results and by running raw data verifications.

Precise Generics is a precision-based enterprise optimizing generic drug development and targeting companion diagnostics to enhance to provide patients and physicians with more efficient alternatives.

Theralink Technologies is a medical diagnostic, and molecular profiling company focused on commercializing innovative biomarker technologies and personalized, precision healthcare information.

Vivacitas is a biopharmaceutical company using artificial intelligence technology and advanced imaging strategies to develop innovative cancer therapies.

COMING SOON

XO Bio Bank is a company that specializes in storing biological specimen while creating a digitally based data used to drive innovation. By using cutting edge bioinformatics, we use Artificial Intelligence to sort large data sets while seeking innovation within personalized medicine and new bioengineered technologies.

Pre-registration for Demo Day in the UAE